Post-stroke depression

Geriatrics and Aging

Volumn 10, Issue 7, 2007, Pages 415-424

  Rothenburg, Lana S ^a   Herrmann, Nathan ^a,b   Lanctôt, Krista L ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c Neuropsychopharmacology Research Program

Author keywords

Depression; Diagnosis; Risk factors; Stroke; Treatment

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CYCLOOXYGENASE 2 INHIBITOR; ESCITALOPRAM; FLUOXETINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; METHYLPHENIDATE; MIANSERIN; MILNACIPRAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ANGINA PECTORIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUING EDUCATION; DEPRESSION; DISEASE SEVERITY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HEART ARRHYTHMIA; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; PHENOMENOLOGY; POSTGRADUATE EDUCATION; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; SYNCOPE; THORAX PAIN; THROMBOCYTE ACTIVATION;

EID: 34547803191     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Johansen HL, Wielgosz AT, Nguyen K, et al. Incidence, comorbidity, case fatality and readmission of hospitalized stroke patients in Canada. Can J Cardiol 2006;22:65-71.
2. Canadian Institute for Health Information. Health Care in Canada. Ottawa: Canadian Institute for Health Information; 2006.
3. Cully JA, Gfeller JD, Heise RA, et al. Geriatric depression, medical diagnosis, and functional recovery during acute rehabilitation. Arch Phys Med Rehabil 2005;86:2256-60.
4. Herrmann N, Black SE, Lawrence J, et al. The Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcome. Stroke 1998;29:618-24.
5. Gillen R, Tennen H, McKee TE, et al. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil 2001;82:1645-9.
6. House A, Knapp P, Bamford J, et al. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 2001;32:696-701.
7. Ghose SS, Williams LS, Swindle RW. Depression and other mental health diagnoses after stroke increase inpatient and outpatient medical utilization three years poststroke. Med Care 2005;43:1259-64.
8. Kong KH, Yang SY. Health-related quality of life among chronic stroke survivors attending a rehabilitation clinic. Singapore Med J 2006;47:213-8.
9. Choi-Kwon S, Kim HS, Kwon SU, et al. Factors affecting the burden on caregivers of stroke survivors in South Korea. Arch Phys Med Rehabil 2005;86:1043-8.
10. House A, Dennis M, Mogridge L, et al. Mood disorders in the year after first stroke. Br J Psychiatry 1991;158:83-92.
11. Gottlieb D, Salagnik I, Kipnis M, et al. Post stroke depression, first year post stroke, in middle band patients. Int J Geriatr Psychiatry 2002;17:486-7.
12. Hackett ML, Yapa C, Parag V, et al. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36:1330-10.
13. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994;151:979-86.
14. Sorenson SB, Rutter CM, Aneshensel CS. Depression in the community: an investigation into age of onset. J Consult Clin Psychol 1991;59:541-6.
15. Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002;159:1862-8.
16. Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 1996;58:99-110.
17. Soderlin MK, Hakala M, Nieminen P. Anxiety and depression in a community-based rheumatoid arthritis population. Scand J Rheumatol 2000;29:177-83.
18. Ramasubbu R, Kennedy SH. Factors complicating the diagnosis of depression in cerebrovascular disease, Part I - Phenomenological and nosological issues. Can J Psychiatry 1994;39:596-600.
19. Primeau F. Post-stroke depression: a critical review of the literature. Can J Psychiatry 1988;33:757-65.
20. Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 2002;52:253-64.
21. Whyte EM, Mulsant BH, Vanderbilt J, et al. Depression after stroke: a prospective epidemiological study. J Am Geriatr Soc 2004;52:774-8.
22. Fure B, Wyller TB, Engedal K, et al. Emotional symptoms in acute ischemic stroke. Int J Geriatr Psychiatry 2006;21:382-7.
23. Starkstein SE, Fedoroff JP, Price TR, et al. Apathy following cerebrovascular lesions. Stroke 1993;24:1625-30.
24. Choi-Kwon S, Han SW, Kwon SU, et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke 2006;37:156-61.
25. Cohen-Cole SA, Stoudemire A. Major depression and physical illness. Special considerations in diagnosis and biologic treatment. Psychiatr Clin North Am 1987;10:1-17.
26. Lipsey JR, Spencer WC, Rabins PV, et al. Phenomenological comparison of poststroke depression and functional depression. Am J Psychiatry 1986;143:527-9.
27. de Coster L, Leentjens AF, Lodder J, et al. The sensitivity of somatic symptoms in post-stroke depression: a discriminant analytic approach. Int J Geriatr Psychiatry 2005;20:358-62.
28. Radloff L. The Centre for Epidemiological Studies Depression Scale. Applied Psychological Measurements 1977;3:385-401.
29. Parikh RM, Eden DT, Price TR, et al. The sensitivity and specificity of the Center for Epidemiologic Studies Depression Scale in screening for post-stroke depression. Int J Psychiatry Med 1988;18:169-81.
30. Shinar D, Gross CR, Price TR, et al. Screening for depression in stroke patients: the reliability and validity of the Center for Epidemiologic Studies Depression Scale. Stroke 1986;17:241-5.
31. Spalletta G, Ripa A, Caltagirone C. Symptom profile of DSM-IV major and minor depressive disorders in first-ever stroke patients. Am J Geriatr Psychiatry 2005;13:108-15.
32. Morris PL, Robinson RG, Andrzejewski P, et al. Association of depression with 10-year poststroke mortality. Am J Psychiatry 1993;150:124-9.
33. Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. Stroke 2005;36:2296-301.
34. Downhill JE, Jr., Robinson RG. Longitudinal assessment of depression and cognitive impairment following stroke. J Nerv Ment Dis 1994;182:425-31.
35. Murata Y, Kimura M, Robinson RG. Does cognitive impairment cause post-stroke depression? Am J Geriatr Psychiatry 2000;8:310-17.
36. Nys GM, van Zandvoort MJ, van der Worp HB, et al. Early depressive symptoms after stroke: neuropsychological correlates and lesion characteristics. J Neurol Sci 2005;228:27-33.
37. Nys GM, van Zandvoort MJ, van der Worp HB, et al. Early cognitive impairment predicts long-term depressive symptoms and quality of life after stroke. J Neurol Sci 2006;247:149-56.
38. Health Canada. A Report on Mental Illnesses in Canada. Ottawa: Health Canada; 2002.
39. Kuehner C. Gender differences in unipolar depression: an update of epidemiological findings and possible explanations. Acta Psychiatr Scand 2003;108:163-74.
40. Robinson RG, Kubos KL, Starr LB, et al. Mood disorders in stroke patients. Importance of location of lesion. Brain 1984;107:81-93.
41. Robinson RG, Starr LB, Lipsey JR, et al. A two-year longitudinal study of post-stroke mood disorders: dynamic changes in associated variables over the first six months of follow-up. Stroke 1984;15:510-17.
42. Robinson RG, Szetela B. Mood change following left hemispheric brain injury. Ann Neurol 1981;9:447-53.
43. Starkstein SE, Robinson RG, Berthier ML, et al. Differential mood changes following basal ganglia vs thalamic lesions. Arch Neurol 1988;45:725-30.
44. Starkstein SE, Robinson RG, Price TR. Comparison of cortical and subcortical lesions in the production of poststroke mood disorders. Brain 1987;110:1045-59.
45. Singh A, Black SE, Herrmann N, et al. Functional and neuroanatomic correlations in poststroke depression: the Sunnybrook Stroke Study. Stroke 2000;31:637-44.
46. Morris PL, Robinson RG, de Carvalho ML, et al. Lesion characteristics and depressed mood in the stroke data bank study. J Neuropsychiatry Clin Neurosci 1996;8:153-9.
47. Schwartz JA, Speed NM, Brunberg JA, et al. Depression in stroke rehabilitation. Biol Psychiatry 1993;33:694-9.
48. Vataja R, Leppavuori A, Pohjasvaara T, et al. Poststroke depression and lesion location revisited. J Neuropsychiatry Clin Neurosci 2004;16:156-62.
49. Lockwood KA, Alexopoulos GS, van Gorp WG. Executive dysfunction in geriatric depression. Am J Psychiatry 2002;159:1119-26.
50. Vataja R, Pohjasvaara T, Mantyla R, et al. Depression-executive dysfunction syndrome in stroke patients. Am J Geriatr Psychiatry 2005;13:99-107.
51. Pohjasvaara T, Leskela M, Vataja R, et al. Post-stroke depression, executive dysfunction and functional outcome. Eur J Neurol 2002;9:269-75.
52. Alexopoulos GS, Meyers BS, Young RC, et al. 'Vascular depression' hypothesis. Arch Gen Psychiatry 1997;54:915-22.
53. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-104.
54. Kimura M, Kanetani K, Imai R, et al. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int Clin Psychopharmacol 2002;17:121-5.
55. Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984;1:297-300.
56. Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005;36:1098-103.
57. Chen Y, Guo JJ, Zhan S, et al. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother 2006;40:2115-22.
58. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;157:351-9.
59. Narushima K, Paradiso S, Moser DJ, et al. Effect of antidepressant therapy on executive function after stroke. Br J Psychiatry 2007;190:260-5.
60. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry 2006;51:923-9.
61. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003;108:939-44.
62. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 1997;102:54-9.
63. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002;19:299-320.
64. Barbui C, Hotopf M, Freemantle N, et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000:CD002791.
65. Grade C, Redford B, Chrostowski J, et al. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998;79:1047-50.
66. Currier MB, Murray GB, Welch CC. Electroconvulsive therapy for post-stroke depressed geriatric patients. J Neuropsychiatry Clin Neurosci 1992;4:140-4.
67. Lincoln NB, Flannaghan T, Sutcliffe L, et al. Evaluation of cognitive behavioural treatment for depression after stroke: a pilot study. Clin Rehabil 1997;11:114-22.
68. Lincoln NB, Flannaghan T. Cognitive behavioral psychotherapy for depression following stroke: a randomized controlled trial. Stroke 2003;34:111-5.
69. Clark MS, Rubenach S, Winsor A. A randomized controlled trial of an education and counselling intervention for families after stroke. Clin Rehabil 2003;17:703-12.
70. Claiborne N. Effectiveness of a care coordination model for stroke survivors: a randomized study. Health See Work 2006;31:87-96.
71. Burton C, Gibbon B. Expanding the role of the stroke nurse: a pragmatic clinical trial. J Adv Nurs 2005;52:640-50.
72. Niedermaier N, Bohrer E, Schulte K, et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry 2004;65:1619-23.
73. Rasmussen A, Lunde M, Poulsen DL, et al. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003;44:216-21.
74. Almeida OP, Waterreus A, Hankey GJ. Preventing depression after stroke: Results from a randomized placebo-controlled trial. J Clin Psychiatry 2006;67:1104-9.
75. Palomaki H, Kaste M, Berg A, et al. Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy. J Neurol Neurosurg Psychiatry 1999;66:490-4.
76. Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 2000;12:588-94.
77. Fujigaki S, Saito K, Sekikawa K, et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 2001;31:2313-8.
78. Liebau C, Baltzer AW, Schmidt S, et al. Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 2002;22:931-6.
79. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004;29:11-7.
80. Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538-44.
81. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007.
82. Nemeth H, Toldi J, Vecsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: pre-clinical and clinical studies. J Neural Transm Suppl 2006:285-304.
83. Jorge RE, Robinson RG, Tateno A, et al. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol Psychiatry 2004;55:398-405.
84. Glodzik-Sobanska L, Slowik A, McHugh P, et al. Single voxel proton magnetic resonance spectroscopy in post-stroke depression. Psychiatry Res 2006;148:111-20.
85. Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression - a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003;250:347-51.
86. Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005;66:708-16.
87. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31:1829-32.
88. Yamakawa Y, Satoh S, Sawa S, et al. Efficacy of milnacipran on poststroke depression on inpatient rehabilitation. Psychiatry Clin Neurosci 2005;59:705-10.